Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Charles Matthews

Neurology Raleigh, NC Medical Doctor

NPI 1891866885 CMS profile 445796

2501 Atrium Dr, Suite 400, Raleigh, NC 27607

Open in the dashboard

General payments

$3,933

354 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Charles Matthews of Raleigh, NC is reported in the CMS Open Payments database as having received $3,933 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $98 5
2022 General $1,393 104
2021 General $1,206 118
2020 General $958 98
2019 General $278 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Matthews
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Charles Matthews were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Charles Matthews Neurology median Middle half National median
2019 $278 $474 $118–$2,177 $163
2020 $958 $367 $82–$2,309 $114
2021 $1,206 $438 $104–$2,547 $132
2022 $1,393 $442 $103–$2,388 $149
2023 $98 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $822 106 payments
  2. Teva Pharmaceuticals USA, Inc. $677 68 payments
  3. Allergan Inc. $430 53 payments
  4. Arbor Pharmaceuticals, Inc. $355 28 payments
  5. Impel Pharmaceuticals Inc. $292 14 payments
  6. Upsher-Smith Laboratories LLC $227 15 payments
  7. Lundbeck LLC $204 13 payments
  8. Supernus Pharmaceuticals, Inc. $185 9 payments
  9. Amgen Inc. $164 10 payments
  10. Biohaven Pharmaceuticals, Inc. $153 13 payments
  11. Other $424 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,817 352 payments
  2. Education $116 2 payments
Products named General payments · program years 2019–2023
  1. UBRELVY Neuroscience $448 69 payments
  2. AJOVY $446 41 payments
  3. UBRELVY Neuroscience $394 51 payments
  4. QULIPTA $366 36 payments
  5. Trudhesa $292 14 payments
  6. NURTEC ODT $272 20 payments
  7. AIMOVIG $217 13 payments
  8. Horizant $204 18 payments
  9. TROKENDI XR $185 9 payments
  10. VYEPTI $177 12 payments
  11. Other $1,268 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record